Clinical trial / 1996
In an open-label trial of 17 Alzheimer's patients, coenzyme nicotinamide adenine dinucleotide (NADH) was reported to improve cognitive dysfunction scores.
An open-label trial evaluated nicotinamide adenine dinucleotide (NADH) medication in 17 patients with dementia of the Alzheimer type for 8 to 12 weeks. All evaluated patients showed improvement in cognitive dysfunction, with Mini-Mental State Examination scores improving by a mean of 8.35 points (range: 6 to 14 points) and Global Deterioration Scale scores improving by a mean of 1.82 (range: 1 to 2 points). No side effects or adverse effects were reported during observation periods exceeding a year in some patients. The authors noted that this pilot study does not allow definitive conclusions and that a double-blind placebo-controlled study is necessary.
- Study type
- Open-label pilot trial
- Who was studied
- 17 patients suffering from dementia of the Alzheimer type
- What was measured
- Cognitive dysfunction (Mini-Mental State Examination, Global Deterioration Scale), adverse effects
THE PAPER
Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type.
Birkmayer JG. Ann Clin Lab Sci, 1996.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.